Real-world treatment outcomes from nationwide Onco-colon Turkey registry in RAS wild-type patients treated with biologics second-line mCRC

Basit Öğe Kaydı
dc.authoridKEFELI, UMUT/0000-0001-6126-5377
dc.authorwosidKEFELI, UMUT/V-6023-2017
dc.contributor.authorYildirim, Mahmut Emre
dc.contributor.authorKaradurmus, Nuri
dc.contributor.authorOkten, Ilker Nihat
dc.contributor.authorTurk, Haci Mehmet
dc.contributor.authorUrakci, Zuhat
dc.contributor.authorArslan, Cagatay
dc.contributor.authorCelik, Sinemis
dc.date.accessioned2024-08-04T20:55:55Z
dc.date.available2024-08-04T20:55:55Z
dc.date.issued2024
dc.departmentİnönü Üniversitesien_US
dc.description.abstractBackgrounds and Objectives Colorectal cancer is one of the leading causes of mortality both globally and in our country. In Turkey, we conducted a multicenter investigation into the effectiveness of second-line treatments and real-life data for patients with RAS wild-type metastatic colorectal cancer (NCT04757311).Materials and Methods In this retrospective analysis, records from 28 centers were collected, and histopathological, molecular, and clinical characteristics were documented. Patients were categorized into groups based on their second-line biological treatments: anti-EGFR (Group A and Group B, panitumumab and cetuximab) and anti-VEGF (Group C, bevacizumab and aflibercept). They were then compared within these groups.Results A total of 588 patients with documented RAS wild-type status were evaluated. The median OS was 15.7, 14.3 and 14.7 months in Group A, Group B and Group C, respectively (p = 0.764). The median PFS of the patients in second-line setting that received panitumumab, cetuximab and bevacizumab/aflibercept were 7.8, 6.6 and 7.4 months, respectively (p = 0.848).Conclusion According to the results of our real-life data study, there is no significant difference in efficiency between the combination of biological agent and chemotherapy used in the second-line treatments.en_US
dc.description.sponsorshipOncology departments in Turkiyeen_US
dc.description.sponsorshipThe authors would like to acknowledge all the support they have received from the Oncology departments in Turkiye.en_US
dc.identifier.doi10.1177/10781552241241004
dc.identifier.issn1078-1552
dc.identifier.issn1477-092X
dc.identifier.pmid38613329en_US
dc.identifier.scopus2-s2.0-85190527263en_US
dc.identifier.scopusqualityQ3en_US
dc.identifier.urihttps://doi.org/10.1177/10781552241241004
dc.identifier.urihttps://hdl.handle.net/11616/101937
dc.identifier.wosWOS:001201466900001en_US
dc.identifier.wosqualityN/Aen_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakScopusen_US
dc.indekslendigikaynakPubMeden_US
dc.language.isoenen_US
dc.publisherSage Publications Ltden_US
dc.relation.ispartofJournal of Oncology Pharmacy Practiceen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectcolon canceren_US
dc.subjecttargeted therapyen_US
dc.subjectRas wild typeen_US
dc.titleReal-world treatment outcomes from nationwide Onco-colon Turkey registry in RAS wild-type patients treated with biologics second-line mCRCen_US
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayın Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu